Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Total Current Liabilities over the past 12 years, most recently at $70.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $70.7 million for Q4 2025, up 47.67% from a year ago — trailing twelve months through Dec 2025 was $70.7 million (up 47.67% YoY), and the annual figure for FY2025 was $70.7 million, up 47.67%.
  • Total Current Liabilities for Q4 2025 was $70.7 million at Viridian Therapeutics, Inc.\DE, up from $50.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for VRDN hit a ceiling of $70.7 million in Q4 2025 and a floor of $13.6 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $27.6 million (2023), compared with a mean of $31.2 million.
  • Biggest five-year swings in Total Current Liabilities: surged 150.33% in 2021 and later fell 20.13% in 2023.
  • Viridian Therapeutics, Inc.\DE's Total Current Liabilities stood at $13.6 million in 2021, then skyrocketed by 144.57% to $33.3 million in 2022, then decreased by 20.13% to $26.6 million in 2023, then soared by 79.74% to $47.9 million in 2024, then surged by 47.67% to $70.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $70.7 million (Q4 2025), $50.7 million (Q3 2025), and $52.6 million (Q2 2025) per Business Quant data.